Skip to Main Content

RAPT Therapeutics, Inc. (NASDAQ: RAPT) SECURITIES FRAUD INVESTIGATION

Kessler Topaz Meltzer & Check, LLP is currently investigating potential violations of the federal securities laws on behalf of purchasers of RAPT Therapeutics, Inc. (NASDAQ: RAPT) (“RAPT”) securities between September 9, 2021 and February 16, 2024.

On February 20, 2024, RAPT issued a press release revealing that the FDA “has verbally notified the company that a clinical hold has been placed on the company’s Phase 2b trial of zelnecirnon (RPT193) in atopic dermatitis and its Phase 2a trial in asthma” and that RAPT “expects to receive a formal clinical hold letter from the FDA.” On this news, RAPT’s stock price fell $5.08 per share, or 10.8%, to close at $41.97 per share on February 20, 2024.

If you have any questions or would like to discuss this investigation, please contact Kessler Topaz Meltzer & Check, LLP:  Jonathan Naji, Esq. (484) 270-1453 or via e-mail at info@ktmc.com.  

Complete this form with your transactions in RAPT Therapeutics, Inc. securities between September 9, 2021 and February 16, 2024

Click Here to Print PDF of this Form

SUBMIT YOUR INFORMATION
* Denotes required field
Date
# of Shares
Price per Share
Date
Principal Amount
Amount Paid
Series or CUSIP
Date
# of Contracts
Price per Contract
Exercise Price
Expiration Date
Did you purchase shares of RAPT Therapeutics, Inc. prior to the Class Period?
Are you a current or former employee of RAPT Therapeutics, Inc.?
The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kessler Topaz or you to file a lead plaintiff motion in this matter. Any information you submit will be maintained as confidential. If Kessler Topaz, in its sole discretion, believes that you might be an appropriate lead plaintiff candidate, Kessler Topaz will contact you to discuss the matter and whether to establish an attorney client relationship. By signing this form you are authorizing us to contact you regarding this case and/or future cases.
I agree to the KTMC disclaimer
I would like to receive new case alerts by email